What a pharma visual aid must carry in India
What UCPMP 2024 Clause 3.2 requires on an Indian pharmaceutical visual aid, quoted from the Code, and the mistakes the format invites.
Where its purpose is to inform a prescribing decision, a visual aid, a detail aid and a leave-behind carry the same UCPMP 2024 Clause 3.2 list. A journal advertisement with that purpose carries the same list. A journal advertisement must also not be designed to disguise its real nature. Where the company pays for, secures or arranges its publication, it must not resemble editorial matter (Clauses 3.3 and 3.4). Patient material and open digital banners that promote a medicine are advertising to the public, which brings in further instruments. The Drugs and Magic Remedies (Objectionable Advertisements) Act 1954 is one. Licence conditions in the Drugs and Cosmetics Rules 1945, are another. They bar any advertisement of Schedule H, H1 or X drugs without the previous sanction of the Central Government (for example Rules 74(p) and 78(q)). Their text sets no audience limit. These pages set out the elements each must carry, and the Code, Act or Rules behind every one of them.
What UCPMP 2024 Clause 3.2 requires on an Indian pharmaceutical visual aid, quoted from the Code, and the mistakes the format invites.
What UCPMP 2024 requires on a pharmaceutical detail aid in India, and why the required list is the same as a visual aid's.
What UCPMP 2024 requires on pharmaceutical leave-behind literature in India, and a correction to a common misconception about company identification.
What UCPMP 2024 requires on a pharmaceutical journal advertisement in India, including the clauses on journal material a company pays for, secures or arranges.
What governs pharmaceutical patient material in India, the two drug-specific instruments that restrict advertising medicines to the public, and the disease list that restricts even non-prescription products.
What UCPMP 2024 requires on a pharmaceutical emailer to doctors in India, including the clause that names mailings directly, and why a medical-supervision caution does not belong on one.
Which instruments govern a pharmaceutical digital banner in India, how the answer changes when the audience is gated to prescribers, and the advertising condition on Schedule H, H1 and X drugs.
When a medical conference poster is an academic disclosure and when it becomes promotional material under UCPMP 2024, and what changes at that line.
General guidance for pharmaceutical marketing teams in India. Regulation and its interpretation change, and this page may not reflect the current position. It is not legal, regulatory or medical advice and it does not replace your own medical, legal and regulatory review. Please verify against the source text before relying on anything here. ImpactPlus Ventures LLP accepts no liability for decisions taken on the basis of this page.